Nika Pharmaceuticals Financials
This page shows Nika Pharmaceuticals (NIKA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Nika Pharmaceuticals passes 1 of 9 financial strength tests. No profitability signals pass, 1 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Nika Pharmaceuticals generates $1.45 in operating cash flow (-$139K OCF vs -$96K net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Nika Pharmaceuticals generated $0 in revenue in fiscal year 2024.
Nika Pharmaceuticals reported -$96K in net income in fiscal year 2024. This represents a decrease of 47.8% from the prior year.
Nika Pharmaceuticals held $2K in cash against $0 in long-term debt as of fiscal year 2024.
Nika Pharmaceuticals had 876M shares outstanding in fiscal year 2024. This represents an increase of 0.0% from the prior year.
NIKA Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | $156 | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | $4K-72.7% | $14K+694.4% | $2K-71.4% | $6K-16.0% | $8K-11.3% | $8K | N/A | $10K |
| Operating Income | -$8K+56.5% | -$18K-42.0% | -$13K-54.7% | -$8K+62.7% | -$22K+51.1% | -$46K | N/A | -$10K |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$8K+56.5% | -$18K-42.0% | -$13K-54.7% | -$8K+62.7% | -$22K+51.1% | -$46K | N/A | -$10K |
| EPS (Diluted) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | N/A | $0.00 |
NIKA Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $24K-25.3% | $32K-9.7% | $35K+95.1% | $18K-95.4% | $390K+841.1% | $41K+111.6% | $20K+79.6% | $11K |
| Current Assets | $24K-25.3% | $32K-9.7% | $35K+95.1% | $18K-91.9% | $222K+435.4% | $41K+111.6% | $20K+79.6% | $11K |
| Cash & Equivalents | $6K-59.7% | $16K-18.4% | $19K+818.7% | $2K-72.2% | $7K-69.4% | $24K+24.9% | $20K+79.6% | $11K |
| Inventory | N/A | N/A | N/A | N/A | $14K-17.1% | $17K | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | $196K | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $284K0.0% | $284K+5.6% | $269K+12.5% | $239K-62.5% | $637K+139.5% | $266K+161.4% | $102K+18.7% | $86K |
| Current Liabilities | $284K0.0% | $284K+5.6% | $269K+12.5% | $239K-62.5% | $637K+139.5% | $266K+161.4% | $102K+18.7% | $86K |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$261K-3.2% | -$253K-7.8% | -$234K-5.9% | -$221K-6.0% | -$209K+7.0% | -$224K-173.3% | -$82K-9.8% | -$75K |
| Retained Earnings | -$9.0M-0.1% | -$9.0M-0.2% | -$8.9M-0.1% | -$8.9M+0.3% | -$9.0M+0.1% | -$9.0M-163.7% | -$3.4M-0.2% | -$3.4M |
NIKA Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$9K+49.6% | -$19K-43.1% | -$13K-4.0% | -$12K+63.3% | -$34K+59.8% | -$84K-1053.2% | -$7K+27.9% | -$10K |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | $0-100.0% | $15K-50.0% | $30K+3.4% | $29K+562.9% | $4K-95.6% | $99K+519.0% | $16K+60.0% | $10K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
NIKA Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | -14395.5% | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | -14395.5% | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -33.9%+24.3pp | -58.1%-21.2pp | -37.0%+566.7pp | -603.7%-597.9pp | -5.8%+105.0pp | -110.8% | N/A | -93.0% |
| Current Ratio | 0.08-0.0 | 0.11-0.0 | 0.13+0.1 | 0.07-0.3 | 0.35+0.2 | 0.16-0.0 | 0.19+0.1 | 0.13 |
| Debt-to-Equity | -1.09+0.0 | -1.13+0.0 | -1.15-0.1 | -1.08+2.0 | -3.05-1.9 | -1.18+0.1 | -1.24-0.1 | -1.15 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$221K), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.07), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Nika Pharmaceuticals's annual revenue?
Nika Pharmaceuticals (NIKA) reported $0 in total revenue for fiscal year 2024. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Nika Pharmaceuticals profitable?
No, Nika Pharmaceuticals (NIKA) reported a net income of -$96K in fiscal year 2024.
What is Nika Pharmaceuticals's earnings per share (EPS)?
Nika Pharmaceuticals (NIKA) reported diluted earnings per share of $0.00 for fiscal year 2024. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Nika Pharmaceuticals's operating cash flow?
Nika Pharmaceuticals (NIKA) generated -$139K in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Nika Pharmaceuticals's total assets?
Nika Pharmaceuticals (NIKA) had $18K in total assets as of fiscal year 2024, including both current and long-term assets.
How many shares does Nika Pharmaceuticals have outstanding?
Nika Pharmaceuticals (NIKA) had 876M shares outstanding as of fiscal year 2024.
What is Nika Pharmaceuticals's current ratio?
Nika Pharmaceuticals (NIKA) had a current ratio of 0.07 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.
What is Nika Pharmaceuticals's debt-to-equity ratio?
Nika Pharmaceuticals (NIKA) had a debt-to-equity ratio of -1.08 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Nika Pharmaceuticals's return on assets (ROA)?
Nika Pharmaceuticals (NIKA) had a return on assets of -534.1% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Nika Pharmaceuticals's cash runway?
Based on fiscal year 2024 data, Nika Pharmaceuticals (NIKA) had $2K in cash against an annual operating cash burn of $139K. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Nika Pharmaceuticals's debt-to-equity ratio negative or unusual?
Nika Pharmaceuticals (NIKA) has negative shareholder equity of -$221K as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Nika Pharmaceuticals's Piotroski F-Score?
Nika Pharmaceuticals (NIKA) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Nika Pharmaceuticals's earnings high quality?
Nika Pharmaceuticals (NIKA) has an earnings quality ratio of 1.45x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.